Evidence map›Paper›PMID 36844366›Full record

ArticleBioactive materials2023

In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles.

Kewa Gao, Jie Li, Hengyue Song, Hesong Han, Yongheng Wang, Boyan Yin, Diana L Farmer, Niren Murthy, Aijun Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Fetal gene therapy.Journal of inherited metabolic disease · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kewa GaoDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Jie LiDepartment of Bioengineering, University of California, Berkeley, CA, 94704, United States.
Hengyue SongDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Hesong HanDepartment of Bioengineering, University of California, Berkeley, CA, 94704, United States.
Yongheng WangDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Boyan YinDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Diana L FarmerDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Niren MurthyDepartment of Bioengineering, University of California, Berkeley, CA, 94704, United States.
Aijun WangDepartment of Surgery, School of Medicine, University of California, Davis, Sacramento, CA, 95817, United States.
Shriners Hospitals for Children · USUniversity of California, Berkeley · USCentral South University · CN

Funding

Gene editing in the brain with CRISPR-PEGR01MH125979 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LEE, HYE YOUNG, MURTHY, NIREN · 2021 to 2025
$3.3M
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida TherapyR01NS115860 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARMER, DIANA LEE, WANG, AIJUN · 2020 to 2024
$2.5M
Development of a Nanoparticle-Based Gene Editing Technology for Neurological ApplicationsUG3NS115599 · NINDS · OHIO STATE UNIVERSITY · PI BANKIEWICZ, KRYSTOF S, MURTHY, NIREN · 2019 to 2021
$2.3M
Single-Cell Transcriptomics of Non-Activated Latently Infected T cells Isolated from HIV+ Drug UsersR61DA048444 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI OTT, MELANIE MARIA · 2019 to 2021
$2.0M
Fetal Tissue Engineering to Treat Spina Bifida Before BirthR01NS100761 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WANG, AIJUN · 2017 to 2021
$1.7M
NIDA NIH HHS R61 DA048444NIMH NIH HHS R01 MH125979NINDS NIH HHS R01 NS100761NINDS NIH HHS R01 NS115860NINDS NIH HHS UG3 NS115599
6 · The paper itself

Abstract

Nanoparticle-based drug delivery systems have the potential to revolutionize medicine, but their low vascular permeability and rapid clearance by phagocytic cells have limited their medical impact. Nanoparticles delivered at the

Indexed as

CRISPR/Cas9Gene editingIn uteromRNA deliveryNanoparticles

Identifiers

PMID36844366
PMCPMC9950423
OpenAlexW4321179396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.